A randomized phase II study comparing trabectedin (T) and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS).
Shunji Takahashi
No relevant relationships to disclose
Nobuhito Araki
No relevant relationships to disclose
Hideshi Sugiura
No relevant relationships to disclose
Takafumi Ueda
Consultant or Advisory Role - Daiichi Sankyo
Honoraria - GlaxoSmithKline
Research Funding - Eisai; GlaxoSmithKline; Taiho Pharmaceutical
Mitsuru Takahashi
No relevant relationships to disclose
Hideo Morioka
No relevant relationships to disclose
Tsukasa Yonemoto
No relevant relationships to disclose
Hiroaki Hiraga
No relevant relationships to disclose
Toru Hiruma
No relevant relationships to disclose
Toshiyuki Kunisada
No relevant relationships to disclose
Akihiko Matsumine
No relevant relationships to disclose
Akira Kawai
Honoraria - Eisai; GlaxoSmithKline; MSD; Taiho Pharmaceutical